Pacira BioSciences, Inc. (PCRX) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Pacira BioSciences, Inc. (PCRX) Bundle
Take control of your Pacira BioSciences, Inc. (PCRX) valuation analysis with our advanced DCF Calculator! Preloaded with real (PCRX) data, this Excel template allows you to adjust forecasts and assumptions to accurately calculate Pacira BioSciences, Inc. (PCRX) intrinsic value.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 421.0 | 420.8 | 541.5 | 666.8 | 675.0 | 719.7 | 767.4 | 818.3 | 872.5 | 930.4 |
| Revenue Growth, % | 0 | -0.04655294 | 28.68 | 23.14 | 1.22 | 6.63 | 6.63 | 6.63 | 6.63 | 6.63 |
| EBITDA | 55.3 | 71.4 | 118.5 | 144.8 | 157.6 | 139.7 | 148.9 | 158.8 | 169.3 | 180.6 |
| EBITDA, % | 13.13 | 16.97 | 21.88 | 21.71 | 23.35 | 19.41 | 19.41 | 19.41 | 19.41 | 19.41 |
| Depreciation | 19.6 | 19.9 | 28.5 | 91.5 | 75.6 | 57.0 | 60.7 | 64.8 | 69.1 | 73.6 |
| Depreciation, % | 4.65 | 4.73 | 5.27 | 13.72 | 11.2 | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 |
| EBIT | 35.7 | 51.5 | 89.9 | 53.3 | 82.0 | 82.7 | 88.2 | 94.1 | 100.3 | 106.9 |
| EBIT, % | 8.48 | 12.24 | 16.61 | 7.99 | 12.15 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 |
| Total Cash | 292.0 | 521.7 | 656.4 | 288.7 | 278.6 | 509.4 | 543.2 | 579.2 | 617.6 | 658.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 47.5 | 53.0 | 96.3 | 98.4 | 105.6 | 103.7 | 110.6 | 118.0 | 125.8 | 134.1 |
| Account Receivables, % | 11.29 | 12.61 | 17.79 | 14.76 | 15.64 | 14.41 | 14.41 | 14.41 | 14.41 | 14.41 |
| Inventories | 58.3 | 64.7 | 98.6 | 96.1 | 104.4 | 111.2 | 118.6 | 126.5 | 134.8 | 143.8 |
| Inventories, % | 13.85 | 15.36 | 18.2 | 14.41 | 15.46 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 |
| Accounts Payable | 12.8 | 10.4 | 10.5 | 15.2 | 15.7 | 17.4 | 18.5 | 19.8 | 21.1 | 22.5 |
| Accounts Payable, % | 3.04 | 2.48 | 1.95 | 2.28 | 2.33 | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 |
| Capital Expenditure | -10.2 | -37.8 | -45.9 | -30.1 | -15.2 | -38.3 | -40.9 | -43.6 | -46.5 | -49.5 |
| Capital Expenditure, % | -2.41 | -8.98 | -8.47 | -4.51 | -2.25 | -5.32 | -5.32 | -5.32 | -5.32 | -5.32 |
| Tax Rate, % | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 |
| EBITAT | 36.6 | 373.2 | 66.9 | 63.7 | 55.8 | 73.2 | 78.0 | 83.2 | 88.7 | 94.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -47.0 | 341.0 | -27.4 | 130.2 | 101.2 | 88.4 | 84.8 | 90.4 | 96.4 | 102.8 |
| WACC, % | 6.9 | 6.9 | 6.49 | 6.9 | 6.38 | 6.72 | 6.72 | 6.72 | 6.72 | 6.72 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 380.4 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 107 | |||||||||
| Terminal Value | 3,937 | |||||||||
| Present Terminal Value | 2,845 | |||||||||
| Enterprise Value | 3,225 | |||||||||
| Net Debt | 433 | |||||||||
| Equity Value | 2,792 | |||||||||
| Diluted Shares Outstanding, MM | 52 | |||||||||
| Equity Value Per Share | 53.72 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real PCRX financials.
- Real-World Data: Access to historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effect of your inputs on Pacira BioSciences’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive DCF Model: Features detailed unlevered and levered DCF valuation frameworks tailored for Pacira BioSciences, Inc. (PCRX).
- WACC Analysis Tool: Pre-configured Weighted Average Cost of Capital spreadsheet with adjustable parameters.
- Customizable Forecast Inputs: Easily alter growth projections, capital investments, and discount rates.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency metrics specific to Pacira BioSciences, Inc. (PCRX).
- Visual Dashboard and Graphs: Graphical representations that encapsulate essential valuation indicators for straightforward assessment.
How It Works
- Download: Obtain the pre-built Excel file containing Pacira BioSciences' financial data.
- Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and analyze results immediately.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose This Calculator for Pacira BioSciences, Inc. (PCRX)?
- Accuracy: Utilizes real Pacira financials to guarantee data precision.
- Flexibility: Built for users to easily test and adjust inputs as needed.
- Time-Saving: Avoid the complexity of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with CFO-level attention to detail and usability.
- User-Friendly: Intuitive design allows even those without advanced financial modeling skills to navigate effortlessly.
Who Should Use Pacira BioSciences, Inc. (PCRX)?
- Investors: Gain insights into the pharmaceutical sector with a reliable investment analysis tool.
- Financial Analysts: Streamline your assessments with a comprehensive financial model tailored for biotech companies.
- Consultants: Easily modify the framework for client-specific presentations or strategic reports.
- Healthcare Enthusiasts: Enhance your knowledge of the biopharmaceutical landscape through detailed case studies.
- Educators and Students: Utilize it as a hands-on resource for courses in finance and healthcare management.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Pacira BioSciences, Inc. (PCRX).
- Real-World Data: Pacira’s historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis focusing on profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Engaging charts and tables providing clear, actionable results.